Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02968121 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia
A Phase 1 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02968121 is a Phase 1 study that was terminated before completion, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 22 participants.
The verdict
NCT02968121, a Phase 1 study, was terminated before completion, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
To determine the pharmacokinetics, safety and tolerability of brexpiprazole administered subcutaneously or intramuscularly in adults with schizophrenia.
Interventions
- DRUG Brexpiprazole, OPDC-34712
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-01 |
| Est. Completion | 2017-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02968121
The ClinicalTrials.gov registry entry for NCT02968121 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brexpiprazole, OPDC-34712 is the first listed.
NCT02968121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02968121 about?
NCT02968121 is a clinical study titled "Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia". To determine the pharmacokinetics, safety and tolerability of brexpiprazole administered subcutaneously or intramuscularly in adults with schizophrenia.
What is the current status of trial NCT02968121?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2017-01. Estimated completion is 2017-12-14.
What interventions are being tested in trial NCT02968121?
The interventions under investigation include: Brexpiprazole, OPDC-34712 (DRUG).
Who is sponsoring clinical trial NCT02968121?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.